{"id":859218,"date":"2025-06-10T16:03:13","date_gmt":"2025-06-10T20:03:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\/"},"modified":"2025-06-10T16:03:13","modified_gmt":"2025-06-10T20:03:13","slug":"xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\/","title":{"rendered":"XPro\u2122 Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer\u2019s Disease: Supported by Department of Defense"},"content":{"rendered":"
\n

\n
\n XPro\u2122 Treatment<\/strong> Post-TBI Prevents Short- and Long-Term Alzheimer\u2019s-like Pathology in transgenic mice<\/b>\n <\/p>\n

\n Boca Raton, Florida, June 10, 2025 (GLOBE NEWSWIRE) — <\/strong> INmune Bio, Inc. (NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient\u2019s innate immune system to fight disease is collaborating with Kirsty Dixon PhD, Assoc Prof. of Surgery at Virginia Commonwealth University in Richmond, Virginia on the interaction of TBI and AD.\u00a0 Prof Dixon and her team presented a poster at the Keystone Symposia\u2019s Neurodegeneration section: Linking Cellular Pathways to Therapeutic Strategies in Whistler, British Columbia, Canada. The poster demonstrates that Traumatic Brain Injury (TBI) increases amyloid deposition in high-risk animals and that administration of XPro\u2122 (XPro1595, pegipanermin<\/em>) significantly reduces amyloid formation and improves clinical measures of brain function.<\/p>\n

Traumatic Brain Injury is a well-established risk factor for Alzheimer\u2019s disease (AD). TBI promotes neuroinflammation, increasing the inflammatory cytokine Tumor Necrosis Factor (solTNF), which has been implicated in AD progression. A key protein in AD pathogenesis is the enzyme \u03b2-secretase (BACE1), which cleaves amyloid precursor protein (APP) to generate neurotoxic amyloid beta (A\u03b242), potentially leading to neuronal loss. Under pathological conditions, TNF receptor 1 (TNFR1) upregulates BACE1 and cell death pathways. Therefore, targeting TBI-induced solTNF\/TNFR1 signaling may mitigate A\u03b242 production and neuronal loss, providing a critical translational link between TBI and AD.<\/p>\n

The study showed that TBI triggered a transient increase in TNFR1, BACE1, and A\u03b242 expression in the hippocampus, peaking three days post-injury and returning to baseline by day seven. Administering XPro\u2122\u00a0thirty minutes post-injury inhibited solTNF\/TNFR1 activity and prevented elevations in TNFR1, BACE1, A\u03b242, and caspase-3 levels. Immunofluorescence revealed that XPro\u2122 treatment reduced intracellular neuronal amyloid accumulation in the hippocampus and improved neurological outcomes in treated animals.<\/p>\n

\u201cOur findings demonstrate that TBI exacerbates amyloidogenesis and behavioral deficits in the hippocampus through solTNF\/TNFR1 signaling,\u201d said Dr. Dixon. \u201cThese results support XPro as a promising treatment to reduce AD pathology risk post-TBI and elucidate a key cellular mechanism linking inflammation to neurodegeneration.\u201d A collaborator to the study Elliott Mufson, PhD, professor of neurobiology, the Greening Chair for Neuroscience Research, and the director of the Alzheimer\u2019s disease research laboratory at Barrow Neurological Institute said, \u201cAn important feature of these findings is that XPro targets neurobehavioral dysfunction resulting from brain trauma and age-related neurodegenerative disease, <\/strong>which holds great promise for people suffering from these disorders.\u201d\u00a0 \u00a0\u00a0<\/p>\n

\u201cTraumatic brain injury from falls is a significant concern for the elderly population at risk for Alzheimer\u2019s disease, as it accelerates dementia onset,\u201d said RJ Tesi, MD, CEO of INmune Bio. \u201cEffectively treating the resulting CNS pathology is critical to preserving cognitive function in this vulnerable group.\u201d<\/p>\n

Poster Number:\u00a02537 Session:\u00a0Poster Session 2:\u00a06\/10\/2025 \u00a0
Neurodegeneration: Linking Cellular Pathways to Therapeutic Strategies;
\u00a0Poster Title: TBI-induced solTNF\/TNFR1 exacerbates Alzheimer\u2019s disease pathophysiology and neurological deficits<\/b>
Authors: Chelsie N. Poffenberger, Subrat Poudel, Michelle M. Taylor, Elliott J. Mufson, Kirsty J. Dixon<\/p>\n

\n About<\/b>\u202fXPro\u2122<\/b>\u00a0<\/p>\n

XPro\u2122 is a next-generation inhibitor of tumor necrosis factor (TNF) that is currently in clinical trial and acts differently than currently available TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro\u2122 could have potential substantial beneficial effects in patients with neurologic disease by decreasing neuroinflammation. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit\u202fthis<\/b>\u202fsection<\/b>\u202fof<\/b>\u202fthe<\/b>\u202fINmune<\/b>\u202fBio\u2019s<\/b>\u202fwebsite<\/b><\/a>.\u00a0<\/p>\n

\n About\u00a0INmune Bio Inc.<\/b>\n <\/p>\n

\n INmune\u00a0Bio\u00a0Inc.<\/a>\u00a0is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer\u2019s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro\u2122). The Natural Killer Cell Priming Platform includes INKmune\u00ae\u00a0developed to prime a patient\u2019s NK cells to eliminate minimal residual disease in patients with cancer and is currently in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom\u2122<\/u>, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal\/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. INmune Bio\u2019s product platforms utilize a precision medicine approach for diseases driven by chronic inflammation and cancer. To learn more, please visit\u00a0www.inmunebio.com<\/a>.<\/p>\n

\n Forward\u00a0Looking\u00a0Statements<\/b>\n <\/p>\n

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDstrom\u2122, XPro1595 (XPro\u2122, pegipanermin<\/em>), and INKmune\u00ae\u2122\u00a0are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company\u2019s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company\u2019s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company\u2019s filings with the Securities and Exchange Commission, including the Company\u2019s Annual Report on Form 10-K, the Company\u2019s Quarterly Reports on Form 10-Q and the Company\u2019s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.<\/p>\n

\n Company Contact:<\/b>\u00a0<\/p>\n

\n David Moss<\/b>\u00a0
Chief Financial Officer<\/b>\u00a0
(561) 710-0512
<\/b>info@inmunebio.com<\/b><\/a>\u00a0
\u00a0
Daniel Carlson<\/b>\u00a0
Head of Investor Relations<\/b>\u00a0
(415) 509-4590<\/b>\u00a0
dcarlson@inmunebio.com<\/b><\/a>\u00a0<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

XPro\u2122 Treatment Post-TBI Prevents Short- and Long-Term Alzheimer\u2019s-like Pathology in transgenic mice Boca Raton, Florida, June 10, 2025 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient\u2019s innate immune system to fight disease is collaborating with Kirsty Dixon PhD, Assoc Prof. of Surgery at Virginia Commonwealth University in Richmond, Virginia on the interaction of TBI and AD.\u00a0 Prof Dixon and her team presented a poster at the Keystone Symposia\u2019s Neurodegeneration section: Linking Cellular Pathways to Therapeutic Strategies in Whistler, British Columbia, Canada. The poster demonstrates that Traumatic Brain Injury (TBI) increases amyloid deposition in high-risk animals and that administration of XPro\u2122 (XPro1595, pegipanermin) significantly reduces … <\/p>\n

Continue reading “XPro\u2122 Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer\u2019s Disease: Supported by Department of Defense”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-859218","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nXPro\u2122 Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer\u2019s Disease: Supported by Department of Defense - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XPro\u2122 Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer\u2019s Disease: Supported by Department of Defense - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"XPro\u2122 Treatment Post-TBI Prevents Short- and Long-Term Alzheimer\u2019s-like Pathology in transgenic mice Boca Raton, Florida, June 10, 2025 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient\u2019s innate immune system to fight disease is collaborating with Kirsty Dixon PhD, Assoc Prof. of Surgery at Virginia Commonwealth University in Richmond, Virginia on the interaction of TBI and AD.\u00a0 Prof Dixon and her team presented a poster at the Keystone Symposia\u2019s Neurodegeneration section: Linking Cellular Pathways to Therapeutic Strategies in Whistler, British Columbia, Canada. The poster demonstrates that Traumatic Brain Injury (TBI) increases amyloid deposition in high-risk animals and that administration of XPro\u2122 (XPro1595, pegipanermin) significantly reduces … Continue reading "XPro\u2122 Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer\u2019s Disease: Supported by Department of Defense"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-10T20:03:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjMzNiM2OTg0MzUyIzUwMDA2ODMyNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"XPro\u2122 Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer\u2019s Disease: Supported by Department of Defense\",\"datePublished\":\"2025-06-10T20:03:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\\\/\"},\"wordCount\":1129,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NjMzNiM2OTg0MzUyIzUwMDA2ODMyNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\\\/\",\"name\":\"XPro\u2122 Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer\u2019s Disease: Supported by Department of Defense - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NjMzNiM2OTg0MzUyIzUwMDA2ODMyNA==\",\"datePublished\":\"2025-06-10T20:03:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NjMzNiM2OTg0MzUyIzUwMDA2ODMyNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NjMzNiM2OTg0MzUyIzUwMDA2ODMyNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XPro\u2122 Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer\u2019s Disease: Supported by Department of Defense\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XPro\u2122 Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer\u2019s Disease: Supported by Department of Defense - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\/","og_locale":"en_US","og_type":"article","og_title":"XPro\u2122 Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer\u2019s Disease: Supported by Department of Defense - Market Newsdesk","og_description":"XPro\u2122 Treatment Post-TBI Prevents Short- and Long-Term Alzheimer\u2019s-like Pathology in transgenic mice Boca Raton, Florida, June 10, 2025 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient\u2019s innate immune system to fight disease is collaborating with Kirsty Dixon PhD, Assoc Prof. of Surgery at Virginia Commonwealth University in Richmond, Virginia on the interaction of TBI and AD.\u00a0 Prof Dixon and her team presented a poster at the Keystone Symposia\u2019s Neurodegeneration section: Linking Cellular Pathways to Therapeutic Strategies in Whistler, British Columbia, Canada. The poster demonstrates that Traumatic Brain Injury (TBI) increases amyloid deposition in high-risk animals and that administration of XPro\u2122 (XPro1595, pegipanermin) significantly reduces … Continue reading \"XPro\u2122 Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer\u2019s Disease: Supported by Department of Defense\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-10T20:03:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjMzNiM2OTg0MzUyIzUwMDA2ODMyNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"XPro\u2122 Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer\u2019s Disease: Supported by Department of Defense","datePublished":"2025-06-10T20:03:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\/"},"wordCount":1129,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjMzNiM2OTg0MzUyIzUwMDA2ODMyNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\/","name":"XPro\u2122 Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer\u2019s Disease: Supported by Department of Defense - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjMzNiM2OTg0MzUyIzUwMDA2ODMyNA==","datePublished":"2025-06-10T20:03:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjMzNiM2OTg0MzUyIzUwMDA2ODMyNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjMzNiM2OTg0MzUyIzUwMDA2ODMyNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xpro-reduces-amyloid-and-enhances-behavior-post-traumatic-brain-injury-in-an-animal-model-of-alzheimers-disease-supported-by-department-of-defense\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"XPro\u2122 Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer\u2019s Disease: Supported by Department of Defense"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/859218","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=859218"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/859218\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=859218"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=859218"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=859218"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}